Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Januar 2018 08:30 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Announces 2018 Outlook and Recent Progress

SEATTLE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for tucatinib, an...
02. Januar 2018 08:30 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency

SEATTLE, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it received a product-specific pediatric...
13. Dezember 2017 08:35 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Added to the Nasdaq Biotechnology Index

SEATTLE, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the...
07. Dezember 2017 16:05 ET | Quelle: Cascadian Therapeutics, Inc.

Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer

SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...
08. November 2017 16:01 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Reports Third Quarter 2017 Financial Results

SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended...
01. November 2017 09:19 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017

SEATTLE, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter financial...
24. Oktober 2017 08:05 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November

SEATTLE, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott D. Myers, President and Chief Executive...
27. September 2017 07:00 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer

SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA")...
20. September 2017 09:00 ET | Quelle: Cascadian Therapeutics, Inc.

Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

SEATTLE, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cantor...
11. September 2017 06:00 ET | Quelle: Cascadian Therapeutics, Inc.

Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress

Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...

Nächste Seite